Ticker: CBPO, Company: China Biologic Products Holdings, Inc., Type: 20-F, Date: 2019-03-06, XBRL Interactive Financials
Original SEC Filing: Click here

---

Webplus: CBPO/20190306/20-F/1/000.htm SEC Original: tv514734_20f.htm

---

---

Webplus: CBPO/20190306/20-F/2_EX-1.1/000.htm SEC Original: tv514734_ex1-1.htm
1.1 THE COMPANIES LAW (2016 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (Adopted by Special Resolution passed on 21 July 2017 THE COMPANIES LAW (2016 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF CHINA BIOLOGIC PRODUCTS

---

---

Webplus: CBPO/20190306/20-F/3_EX-4.40/000.htm SEC Original: tv514734_ex4-40.htm
Employment Agreement Agreement Company Executive This Employment Agreement (this “ WHEREAS, the Company desires to engage the Executive as, and the Executive agrees to serve as, Chief Executive Officer of the Company, upon the terms and conditions contained herein. NOW THEREFORE, for good and valuable consideration, the sufficiency of which is hereby acknowledged by the parties, the parties hereby agree

---

---

Webplus: CBPO/20190306/20-F/4_EX-4.41/000.htm SEC Original: tv514734_ex4-41.htm
Third Amended and Restated Employment Agreement Agreement Company Executive This Third Amended and Restated Employment Agreement (this “ 2012 Agreement WHEREAS, the Company and the Executive entered into an employment agreement dated as of August 31, 2012 (the “ 2014 Agreement 2016 Agreement WHEREAS, the Company and the Executive entered into a renewal employment agreement dated as of August 31,

---

---

Webplus: CBPO/20190306/20-F/5_EX-4.42/000.htm SEC Original: tv514734_ex4-42.htm
Employment Agreement Agreement Company Executive This Employment Agreement (this “ WHEREAS, the Company desires to engage the Executive as, and the Executive agrees to serve as, Executive Vice President and Chief Business Officer of the Company, upon the terms and conditions contained herein. NOW THEREFORE, for good and valuable consideration, the sufficiency of which is hereby acknowledged by the parties,

---

---

Webplus: CBPO/20190306/20-F/6_EX-8.1/000.htm SEC Original: tv514734_ex8-1.htm
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC Jurisdiction of Incorporation or Name Organization Taibang Biological Ltd. British Virgin Islands Taibang Holdings (Hong Kong) Limited Hong Kong Health Forward Holdings Limited Hong Kong TianXinFu (Beijing) Medical Appliance Co., Ltd. PRC Taibang Biotech (Shandong) Co., Ltd. PRC Taibang (Beijing) Pharmaceutical Research Institute Co., Ltd. PRC Shandong Taibang Biological Products Co., Ltd. PRC Qihe Antai

---

---

Webplus: CBPO/20190306/20-F/7_EX-11.1/000.htm SEC Original: tv514734_ex11-1.htm
CODE OF ETHICS CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. I. Objectives Company China Biologic Products Holdings, Inc. and its subsidiaries (together, the “ Code Covered Persons This Code of Ethics (“ · honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; · Commission · compliance with applicable governmental laws, rules

---

---

Webplus: CBPO/20190306/20-F/8_EX-12.1/000.htm SEC Original: tv514734_ex12-1.htm
Certification by the Chief Executive Officer I, Bing Li, certify that: 1. I have reviewed this annual report on Form 20-F of China Biologic Products Holdings, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in

---

---

Webplus: CBPO/20190306/20-F/9_EX-12.2/000.htm SEC Original: tv514734_ex12-2.htm
Certification by the Chief Financial Officer I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 20-F of China Biologic Products Holdings, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in

---

---

Webplus: CBPO/20190306/20-F/10_EX-13.1/000.htm SEC Original: tv514734_ex13-1.htm
Certification by the Chief Executive Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

---

Webplus: CBPO/20190306/20-F/11_EX-13.2/000.htm SEC Original: tv514734_ex13-2.htm
Certification by the Chief Financial Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. By

---

---

Webplus: CBPO/20190306/20-F/12_EX-15.1/000.htm SEC Original: tv514734_ex15-1.htm
Consent of Independent Registered Public Accounting Firm The Board of Directors Revenue from Contracts with Customers Our report on the consolidated financial statements refers to a change in the Company’s method of accounting for revenue recognition in 2018 due to the adoption of ASU No. 2014-09, Our report on the effectiveness of internal control over financial reporting as of December

---

Company Info:

Ticker: CBPO, Company: China Biologic Products Holdings, Inc., Type: 20-F, Date: 2019-03-06, XBRL Interactive FinancialsCIK: 0001369868, Location: F4, SIC: 2836, SIC Desc: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Business Phone & Address:
18TH FL, JIALONG INTERNATIONALBUILDING, 19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT
BEIJING 100125